Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings

Cancer Cytopathology

Volumn 123, Issue 10, 2015, Pages 620-628

  Kawahara, Akihiko ^a   Fukumitsu, Chihiro ^a   Taira, Tomoki ^a   Abe, Hideyuki ^a   Takase, Yorihiko ^a   Murata, Kazuya ^a   Yamaguchi, Tomohiko ^a   Azuma, Koichi ^b   Ishii, Hidenobu ^b   Takamori, Shinzo ^b   Akiba, Jun ^b   Hoshino, Tomoaki ^b   Kage, Masayoshi ^a  

^a KURUME UNIVERSITY HOSPITAL   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cytology cell free DNA; epidermal growth factor receptor mutation; liquid based cytology; lung cancer; supernatant fluid

Indexed keywords

CASPASE 3; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN CCFDNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CANCER CELL; CANCER CELL LINE; CELL DAMAGE; CONTROLLED STUDY; CYTOLOGY; DNA DETERMINATION; DNA EXTRACTION; DNA FRAGMENTATION; ENZYME MODIFICATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEDIMENT; SENSITIVITY AND SPECIFICITY; SUPERNATANT; TRACHEOBRONCHIAL TOILET; VERY ELDERLY; ADENOCARCINOMA; BRONCHUS; CANCER STAGING; CELL FREE SYSTEM; CYTODIAGNOSIS; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRONCHI; CELL-FREE SYSTEM; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84950277953     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21583     Document Type: Article

References (23)

1. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
2. Lindeman NI, Cagle PT, Beasley MB, et al., Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013; 15: 415-453.
3. Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K,. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer. 2013; 82: 294-298.
4. Kuiper JL, Heideman DA, Thunnissen E, et al., Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer. 2014; 85: 19-24.
5. Huang ZH, Li LH, Hua D,. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006; 243: 64-70.
6. Mead R, Duku M, Bhandari P, et al., Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011; 105: 239-245.
7. Kimura H, Kasahara K, Kawaishi M, et al., Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006; 12: 3915-3921.
8. Soh J, Toyooka S, Aoe K, et al., Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006; 119: 2353-2358.
9. Kimura H, Fujiwara Y, Sone T, et al., EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006; 95: 1390-1395.
10. Jian G, Songwen Z, Ling Z, et al., Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010; 136: 1341-1347.
11. Aikawa E, Kawahara A, Hattori S, et al., Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol. 2011; 119: 335-345.
12. Kawahara A, Taira T, Abe H, et al., Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry. Cancer Cytopathol. 2014; 122: 145-152.
13. Kawahara A, Yamamoto C, Nakashima K, et al., Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010; 16: 3163-3170.
14. Kawahara A, Azuma K, Sumi A, et al., Identification of non-small cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011; 74: 35-40.
15. Didelot A, Le Corre D, Luscan A, et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol. 2012; 92: 275-280.
16. Roma C, Esposito C, Rachiglio AM, et al., Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int. 2013; 2013: 385087.
17. Kitano S, Nakayama M, Yamane A, Tsukahara Y, Amano M,. Detection of DNA mutations by fluorescence resonance energy transfer-based preferential homoduplex formation assay. Anal Biochem. 2011; 408: 197-205.
18. Kawahara A, Taira T, Azuma K, et al., A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012; 78: 39-44.
19. Sakai K, Horiike A, Irwin DL, et al., Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 2013; 104: 1198-1204.
20. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al., Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol. 2012; 7: 1369-1381.
21. Wang C, Duan Q, Kelly M, Duggan MA,. Accuracy of bronchial brush and wash specimens prepared by the ThinPrep method in the diagnosis of pulmonary small cell carcinoma. Cancer Cytopathol. 2014; 122: 577-585.
22. Bellevicine C, Bianco A, Malapelle U, et al., Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. Cytopathology. 2015; 26: 99-105.
23. Liu D, Lu Y, Hu Z, et al., Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma. PLoS One. 2014; 9: e89946.